Masahito Kotaka

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Daisuke Kotani, Eiji Oki, Yoshiaki Nakamura et al. · Nature Medicine · 2023 · 430 citations · Full text

Surgical Oncology, Oncology, Cancer Epidemiology +15

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

Rui‐Hua Xu, Kei Muro, Satoshi Morita et al. · The Lancet Oncology · 2018 · 157 citations

Medicine, Pharmacology, Clinical Trials +10

Early Results of Intersphincteric Resection for Patients with Very Low Rectal Cancer: An Active Approach to Avoid a Permanent Colostomy

Norio Saito, Masato Ono, Masanori Sugito et al. · Diseases of the Colon & Rectum · 2004 · 135 citations

ctDNA-based molecular residual disease and survival in resectable colorectal cancer

Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa et al. · Nature Medicine · 2024 · 132 citations · Full text

Interim Analysis, Prognostic Biomarkers, Surgical Oncology +14

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

Takayuki Yoshino, Takeharu Yamanaka, Eiji Oki et al. · JAMA Oncology · 2019 · 96 citations · Full text